This is NOT a game changer

This is NOT a game changer

The news that AstraZeneca (NYSE:AZN) has received FDA approval for the Bydureon® pen delivery system has created quite the stir in the diabetes world. While this is a positive step for Astra having the pen available is not the game changer that some seem to think it is. Keep in mind that the GLP-1 market is getting very crowded and Astra is still trying to figure out a comprehensive diabetes strategy.

Yes there was a time when Diabetic Investor thought having the pen delivery system for Bydureon could have been a game changer but that time has come and gone. Lilly (NYSE:LLY) and GlaxoSmithKline (NYSE:GSK) now have long-acting GLP-1’s before the FDA while Novo Nordisk (NYSE:NVO) continues to promote Victoza aggressively. The simple fact is all the changes with who owned Bydureon has cost the drug dearly as it never had a clear strategy.

The battle for the GLP-1 market is really no different than the insulin or oral medication markets, this is no longer about who has the “best” drug or most convenient delivery system.  Winners and losers in the diabetes drug market will be determined by who can navigate the complex waters of reimbursement, pricing and rebates.